Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals (INO) is a biotechnology innovator developing DNA-based immunotherapies targeting cancer, infectious diseases, and HPV-related conditions. This page aggregates all company announcements, clinical trial updates, and strategic developments for stakeholders.
Access real-time updates on INO's pioneering electroporation-delivered therapies, financial results, and regulatory milestones. Our curated news collection includes press releases, clinical research progress, corporate partnerships, and earnings reports, providing a holistic view of the company's trajectory.
Investors and researchers can efficiently track INO's progress in advancing DNA medicines through phase trials and commercialization efforts. Bookmark this page for streamlined monitoring of developments impacting INO's position in the biotech sector.
INOVIO (NASDAQ: INO) reported its Q2 2025 financial results and provided key business updates. The company is on track to submit a Biologics License Application (BLA) for INO-3107 in the second half of 2025, targeting FDA file acceptance by year-end. The company completed design verification testing of CELLECTRA® 5PSP device and requested rolling submission from FDA.
Financial highlights include a reduced net loss of $23.5 million ($0.61 per share) compared to $32.2 million in Q2 2024. R&D expenses decreased to $14.5 million from $23.1 million, and G&A expenses reduced to $8.6 million from $10.2 million. The company raised $22.5 million through a public offering in July 2025, with total cash position of $47.5 million as of June 30, 2025.
Clinical data for INO-3107 showed impressive results, with 86% of patients experiencing 50-100% reduction in surgeries by Year 2, and 50% achieving complete response. The company expects potential commercial launch in 2026 pending FDA approval.
INOVIO (NASDAQ: INO) published promising long-term data in The Laryngoscope for its DNA medicine INO-3107 in treating Recurrent Respiratory Papillomatosis (RRP). The retrospective study showed significant improvements in patient outcomes, with the Overall Response Rate increasing to 86% in Year 2 from 72% in Year 1, and Complete Response rate rising to 50% from 28%.
The mean number of required surgeries decreased substantially from 4.1 per year pre-treatment to 1.7 in Year 1 and 0.9 in Year 2. The study followed 28 patients with a median follow-up of 2.8 years, demonstrating continued improvement trends into Year 3. Importantly, INO-3107 was well-tolerated with no serious adverse events reported.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancers, and infectious diseases, will release its Q2 2025 financial results on August 12, 2025 after market close.
The company will host a conference call and webcast at 4:30 p.m. ET the same day, featuring a general business update and analyst Q&A session. Investors can access the live webcast through INOVIO's investor relations website, with a replay available for 90 days post-event.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the upcoming Orphan Drug Summit in Boston, Massachusetts. The company will present on July 16 at 4:30 PM ET, focusing on their DMAb Technology and its transformational potential in rare disease treatment.
The presentation will explore the capabilities of next generation DNA medicine technology in addressing rare diseases, as part of a conference that brings together industry leaders and innovators to discuss technological and manufacturing advancements in the rare disease space.
INOVIO Pharmaceuticals (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has announced the pricing of a $25 million public offering. The offering consists of 14,285,715 shares of common stock along with Series A and Series B warrants, all priced at $1.75 per share.
The warrants allow holders to purchase up to an additional 14,285,715 shares each at an exercise price of $1.75. The underwriters, led by Piper Sandler & Co., have a 30-day option to purchase up to 2,142,857 additional shares and corresponding warrants. The offering is expected to close around July 7, 2025.
INOVIO Pharmaceuticals (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock (or pre-funded warrants), along with accompanying Series A and Series B warrants.
The company will grant the underwriter, Piper Sandler & Co., a 30-day option to purchase up to an additional 15% of the securities. The offering will be conducted under a shelf registration statement that was declared effective on January 31, 2024. The final size and terms of the offering will depend on market conditions.
INOVIO (NASDAQ: INO) reported its Q1 2025 financial results and business updates. The company is on track to begin rolling submission of its Biologics License Application (BLA) for INO-3107, a potential treatment for recurrent respiratory papillomatosis (RRP), in mid-2025. Key financial metrics show a net loss of $19.7 million ($0.51 per share), improved from $30.5 million loss in Q1 2024. Operating expenses decreased to $25.1 million from $31.5 million year-over-year.
The company reported promising interim results from its Phase 1 trial of DNA-encoded monoclonal antibodies (DMAbs), showing long-lasting in vivo production. Cash position stands at $68.4 million as of March 31, 2025, expected to support operations into Q1 2026. INOVIO anticipates FDA file acceptance by year-end 2025, with potential approval (PDUFA date) in mid-2026 if granted priority review.
INOVIO, a biotechnology company developing DNA medicines, has announced its participation in several major scientific and investor conferences in May 2025. The company will present at the Citizens JMP Life Sciences Conference in New York through a fireside chat on May 8.
Notably, INOVIO will showcase new data about their lead candidate INO-3107 at multiple venues. Key presentations include:
- European Laryngological Society Annual Congress: Results showing 81% surgery reduction in adults with recurrent respiratory papillomatosis
- American Society of Gene and Cell Therapy: Treatment outcomes for recurrent respiratory papillomatosis
- American Broncho-Esophagological Association: Long-term clinical effects of INO-3107 in treating HPV 6 & 11-caused respiratory papillomatosis
Abstracts will be available on INOVIO's website after presentations, with the JMP conference webcast replay accessible for 90 days.
INOVIO (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company, which focuses on developing treatments for HPV-associated diseases, cancers, and infectious diseases, will host a live conference call and webcast at 4:30 p.m. ET on the same day. The event will include:
- A general business update presentation
- Live Q&A session with analysts
- Webcast access through http://ir.inovio.com/events-and-presentations/default.aspx
The webcast will be available for replay for 90 days following the event. This listen-only event provides investors and stakeholders an opportunity to stay updated on INOVIO's financial performance and business developments.
INOVIO (NASDAQ:INO) has announced its participation in several upcoming scientific conferences to present data on its lead candidate INO-3107 and DNA medicine technologies. At the National HPV Conference in Indianapolis on April 15, the company will present results showing a 72% overall response rate in Year 1 for treating Recurrent Respiratory Papillomatosis caused by HPV-6 & 11.
The company will also participate in the World Vaccine Congress in Washington, DC (April 21-23), where they will discuss their DNA-encoded monoclonal antibody (DMAb™) technology and DNA immunotherapeutics for cancer and viral diseases. Additionally, INOVIO will present at the Festival of Biologics in San Diego on April 23, focusing on INO-3107 for Recurrent Respiratory Papillomatosis. Abstracts will be available on INOVIO's website after the presentations.
FAQ
What is the current stock price of Inovio Pharmaceu (INO)?
What is the market cap of Inovio Pharmaceu (INO)?
